Economy
Financial Markets
Commodities
Industries
Energy
Real Estate
Local listed Company
Overseas-listed Company
Foreign Company
Industrial Parks


 
Stocks / IPOs
 Search News  Or
China National Biotech eyes RMB 9.98 bln via Hong Kong IPO

May. 18, 2012 (China Knowledge) - China National Biotech Group (CNBG), a unit of state-owned China National Pharmaceutical Group Corp or Sinopharm, plans to raise between RMB 8.31 billion and RMB 9.98 billion through an initial public offering on the Hong Kong Stock Exchange, sources reported.

CNBG, China’s largest biotech company and the world’s fourth largest maker of vaccines, plans to use proceeds from the deal to fund the construction of production bases, potential acquisitions, research and development, and to replenish its working capital.

Media reports said late last year that the company is expected to launch the IPO in the first half of this year.

The company owns six institutes located in major Chinese cities and makes more than 200 drugs, vaccines and diagnostics. In 2010, the firm booked RMB 722 million in profit and RMB 5 billion in revenue.







Add this     
Copyright © "2015" www.chinaknowledge.com

Send feedback or comments to: news@chinaknowledge.com

For more news, financial weekly reports, business guides to China, Market Research Reports and other premium information, subscribe to China Knowledge today

To access our page on Bloomberg, type CKFI (GO)

 Our Professional Services

 E-Store

 News Archive
About Us | CSR | Media Center | E-Newsletter | E-Store | Contact Us | Feedback | Sitemap | Privacy Policy | Terms of Use  

           Copyright © 2014 China Knowledge Online. All Rights Reserved